CTOs on the Move

Acucela

www.acucela.com

 
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.acucela.com
  • 1301 2nd Ave # 1900
    Seattle, WA USA 98101
  • Phone: 206.805.8300

Executives

Name Title Contact Details

Similar Companies

IncisionTech

IncisionTech is a Staunton, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mission Search USA

Mission Search USA is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.

Catalyst Biosciences

Catalyst Biosciences is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in South San Francisco, CA. To find more information about Catalyst Biosciences, please visit www.catbio.com

Royal Ottawa Health Care Group

Royal Ottawa Health Care Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.